Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology.
about
Remedial applications of silencing ribonucleic acids and modalities for its delivery to the kidneys--a reviewRNAi reduces expression and intracellular retention of mutant cartilage oligomeric matrix protein.Anti-CD22 antibody targeting of pH-responsive micelles enhances small interfering RNA delivery and gene silencing in lymphoma cellsUtilization of monoclonal antibody-targeted nanomaterials in the treatment of cancer.Carrier-free cellular uptake and the gene-silencing activity of the lipophilic siRNAs is strongly affected by the length of the linker between siRNA and lipophilic group.Concepts in in vivo siRNA delivery for cancer therapy.Cholesterol-Containing Nuclease-Resistant siRNA Accumulates in Tumors in a Carrier-free Mode and Silences MDR1 Gene.Receptor-mediated therapeutic transport across the blood-brain barrier.Potential clinical applications of siRNA technique: benefits and limitations.siRNA therapeutics in the treatment of diseases.Oligonucleotide conjugates for therapeutic applications.Streptavidin-biotin technology: improvements and innovations in chemical and biological applications.Neuronal and vascular interactions.Advances in the delivery of RNA therapeutics: from concept to clinical reality.The principles and applications of avidin-based nanoparticles in drug delivery and diagnosis.In vitro investigations of the efficacy of cyclodextrin-siRNA complexes modified with lipid-PEG-Octaarginine: towards a formulation strategy for non-viral neuronal siRNA delivery.Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA.Sustained local delivery of siRNA from an injectable scaffold.Targeted brain delivery of itraconazole via RVG29 anchored nanoparticles.Internalization of biotinylated compounds into cancer cells is promoted by a molecular Trojan horse based upon core streptavidin and clostridial C2 toxin.Understanding barrier mechanisms in the developing brain to aid therapy for the dysfunctional brain
P2860
Q26995395-DD1A0A06-2E0A-40E8-AEC2-6BB316CC3114Q33565464-028C1712-2602-4F3E-9DCB-41EA0C429DFBQ35144394-FB7DB9DA-4DC3-410E-AD96-CAD34ADF2C30Q35578037-BA7F3E94-FB5D-4870-A2E4-53A2AC7CAC9BQ35823611-75ACEB80-B0AF-4BAE-A9DC-DF68A4CA0D44Q37217876-E99448F3-B57D-4093-944C-EF413155ECA0Q37718210-80F0FE7E-141B-4DA1-AEAA-A7BED98A358DQ37773246-2ED2757B-B127-4055-B561-E6C4F068DC30Q37801965-C2D3D049-9494-4C16-A754-44EE6CC9D26BQ38074462-C68BC07A-45AF-499E-B8C2-4D243DA1E311Q38123854-55ACC17C-593D-4754-A2E4-D40B7B3F7358Q38140695-3EE8B9AC-1980-4089-A8FD-6B9FA8345D5AQ38381835-B7243C34-5DB4-4D03-A1F9-03C48C138D9BQ38706445-9E17C153-0AE8-40BE-9059-53FFEB0F95D2Q39014347-904FFA49-25F0-4015-B593-B0F18915DC25Q39236255-1E3AD7A1-42FB-491E-91CB-E6CD46CE48C4Q39505101-C4AE0FF0-7898-4C10-A145-2F05574525B3Q39641314-6C0705E5-F9A4-4969-ADCA-C17706B4D083Q48169419-02B655D5-A458-451E-B8C3-7D78EF2FB223Q51770492-2D59E5C8-66A2-4DD5-8035-7CCD4542DA58Q57199920-D191A32D-EC04-406E-9345-035588F59F9B
P2860
Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Antibody-mediated targeting of ...... sing avidin-biotin technology.
@en
Antibody-mediated targeting of ...... sing avidin-biotin technology.
@nl
type
label
Antibody-mediated targeting of ...... sing avidin-biotin technology.
@en
Antibody-mediated targeting of ...... sing avidin-biotin technology.
@nl
prefLabel
Antibody-mediated targeting of ...... sing avidin-biotin technology.
@en
Antibody-mediated targeting of ...... sing avidin-biotin technology.
@nl
P2860
P356
P1476
Antibody-mediated targeting of ...... sing avidin-biotin technology.
@en
P2093
Chun-Fang Xia
P2860
P304
P356
10.1021/MP800194Y
P407
P577
2009-05-01T00:00:00Z